The ADHD titration platform that turns between-visit silence into a converging signal. Structured daily telemetry, panel triage, and a decision log — embedded in your EHR, sovereign to the prescriber. Pharmacogenomic reference cards layer on when a phenotype is on file — optional, never required.
Patients keep imperfect journals. Prescribers make dose decisions from memory and one 15-minute check-in. Everyone loses weeks. Some quit.
Median duration of an ADHD medication titration cycle — largely driven by check-in cadence, not clinical complexity.
Of adults starting ADHD pharmacotherapy discontinue within 90 days — before their dose ever converges.
Higher plasma exposure in CYP2D6 poor metabolizers on atomoxetine — when a phenotype is on file, Titrately surfaces the CPIC card.
CYP2D6 poor metabolizer prevalence. Most patients don't know. Many arrive with a prior test result.
To reach a stable dose. Titrately's design target: two.
Four purpose-built controls. No streaks. No gamification. No engagement mechanics that turn medical adherence into a video game.
Panel-wide triage ranks patients by clinical urgency — tolerability flags, adherence patterns, pending titration decisions. Everyone stable disappears from view.
Titrately's core value ships without any genetic testing. Structured telemetry alone compresses titration. When a CYP2D6 or CYP2C19 phenotype is on file, the PK reference cards surface. When it isn't, they don't. Simple as that.
Reduced CYP2D6 activity leads to 2.4× higher atomoxetine plasma AUC and prolonged half-life. Onset of therapeutic effect and side-effect windows shift.
We don't sample. We don't test. The phenotype comes from wherever the patient's record already lives — or nowhere at all, and the platform still delivers full value.
Patient arrives with a prior GeneSight, Genomind, or Tempus panel — or a DTC genotype, or an EHR-imported FHIR observation. Prescriber enters the phenotype at episode start. Cards appear.
Clinical suspicion of PM/UM. First-line med failed. Preemptive testing at intake. Buccal swab or blood draw. Results in 3–7 days, ~$150–$300 (often reimbursed for psychiatric indications).
Most titrations don't require PGx to succeed. The timeline, triage, and decision log deliver full value without any phenotype data. Cards simply don't fire — nothing else changes.
Titrately embeds inside your platform via SMART-on-FHIR & OAuth 2.0. Your prescribers never leave your workflow. Your data-residency and RLS-by-host_id boundaries hold. Your brand stays central. We are the module — you are the platform.
Talk to integration →Titrately stays on the clinical decision support side of the FDA line. Not because we're timid — because it's the honest position for a reference engine.
No output says "reduce to X" or "switch to Y." Only: literature reference for this phenotype and this drug.
Every observation is framed as telemetry ready for review or reference material for clinical judgment.
Every PK card links to the published CPIC guideline or PharmGKB annotation. Verify independently, in one click.
"PK reference only. Not a treatment recommendation. Clinical decision rests with the prescriber." Every card. Every time.
Between visits, my ADHD patients live in a fog and I live in an inbox. Titrately is the first tool that lets us both meet at a signal, not a story.
Prescriber sovereignty preserved. RLS-by-host_id. SMART-on-FHIR. Your brand stays central. Our engine stays reference-only. Ask about the pilot programme.
Self-hosted or fully-managed instance. Bring your own EHR or use our lightweight cockpit. HIPAA-ready. Priced per active titration, not per seat.